Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
Wang Xiaodong, Chair of the Scientific Advisory Board at BeiGene Ltd. (NASDAQ:ONC) (NASDAQ:BGNE), recently sold a significant portion of the company’s American Depositary Shares. The transactions, executed on April 14, 2025, were completed under a Rule 10b5-1 trading plan adopted on August 12, 2024.
Wang disposed of a total of 33,319 shares at prices ranging from $237.561 to $249.4529 per share, generating approximately $10.1 million. Following these sales, Wang holds 365 American Depositary Shares directly.
Additionally, Wang exercised options to acquire 54,288 Ordinary Shares at a price of $6.50 per share, totaling $271,440. These transactions reflect Wang’s continued involvement with the company, as he maintains a substantial shareholding in BeiGene through various direct and indirect holdings.
In other recent news, BeiGene Ltd reported a significant 55% increase in total revenue for 2024, reaching $3.8 billion, with a notable 77% growth in product revenue during the fourth quarter. This performance underscores the company’s strong market strategies and expansion efforts, particularly in the U.S., which contributed 55% of Q4 revenues. Additionally, BeiGene completed an $800 million manufacturing facility, further solidifying its operational capabilities. Looking ahead, the company projects 2025 revenue between $4.9 billion and $5.3 billion, with plans to maintain stable pricing for its product Brukinsa.
In terms of analyst activity, BeiGene’s strategic advancements and financial performance reflect positively on its market position, with analysts from Jefferies and Morgan Stanley (NYSE:MS) acknowledging its robust growth trajectory. The company has also introduced 13 new molecular entities to the clinic in 2024, demonstrating its commitment to innovation and product development. BeiGene’s strong cash position of $2.6 billion at the end of 2024 supports its ongoing growth and research initiatives. The company plans multiple Phase III trials in chronic lymphocytic leukemia and mantle cell lymphoma, aligning with its strategic focus on expanding its product pipeline and market reach.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.